|
|
|
|
|
Elocon: profile and news
Schering-Plough Reports Financial Results for 2005 Fourth Quarter ... Jan 30, 2006 Schering-Plough Reports 2005 Third Quarter Financial Results Oct 24, 2005 Fougera Announces Approval of Mometasone Furoate Cream and ... Apr 11, 2005 Schering-Plough Reports Financial Results for 2005 First Quarter Apr 21, 2005 FDA approves Asmanex for once-daily treatment of asthma Apr 3, 2005 Fougera Announces Approval of Mometasone Furoate Cream and ... Apr 11, 2005 Asthma - FDA Approves ASMANEX(R) (mometasone furoate) for Once ... Apr 1, 2005 Perrigo Company Announces FDA Approval For Mometasone Furoate ... Apr 11, 2005 Taro posts $77.7m Q4 revenue Feb 24, 2005 Taro Reports 4th Quarter and Full Year 2004 Results Feb 24, 2005 Other information Indication For the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older (as an inhalant). Also used as a cream/ointment for the relief of inflammatory and pruritic manifestations of dematoses. Pharmacology Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g. mast cells, eosinophils, neutrophils, macrophages and lymphocytes) and mediators (e.g. histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma and in skin lesions. Mechanism Of Action Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. Drug Category Anti-allergic Agents; Anti-inflammatory Agents; ATC:D07AC13; ATC:D07XC03; Brand Names/Synonyms Asmanex Twisthaler; Combisor; Elocom; Elocon; Mometasone; Mometasone Furoate; Nasonex Dosage Forms CREAM; LOTION; METERED-DOSE (PUMP); OINTMENT Absorption Nasal spray is virtually undetectable in plasma Interactions Interactions for Mometasone: In clinical studies, the concurrent administration of the ASMANEX® TWISTHALER® inhaler and other drugs commonly used in the treatment of asthma was not associated with any unusual adverse events. However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing. Chemical IUPAC Name 9-chloro-17-(2-chloroacetyl)-11,17-dihydroxy-10,13,16-trimethyl-6,7,8, 11,12, Chemical Formula C22H28Cl2O4 Half Life 5.8 hours Drug Type Approved Drug # Accession No APRD00289 CAS Registry Number 105102-22-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |